Article

(2021) COVID-19 and antimalarials. Have we been doing it wrong all along? European Journal of Pharmacology. p. 4. ISSN 0014-2999

(2021) Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID-19. J Cell Mol Med. pp. 591-595. ISSN 1582-1838 (Print) 1582-1838

(2021) Rationale for Effective Prophylaxis Against COVID-19 Through Simultaneous Blockade of Both Endosomal and Non-Endosomal SARS-CoV-2 Entry into Host Cell. Cts-Clinical and Translational Science. pp. 431-433. ISSN 1752-8054

(2020) Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management? European Journal of Pharmacology. p. 4. ISSN 0014-2999

(2020) Glucose-6-phosphate dehydrogenase deficiency and SARS-CoV-2 mortality: Is there a link and what should we do? Clinical Biochemistry. pp. 31-33. ISSN 0009-9120

(2020) Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID-19: Shoot the messenger! Journal of Cellular and Molecular Medicine. pp. 10267-10269. ISSN 1582-1838

(2020) Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2. Archives of Medical Science. pp. 519-521. ISSN 1734-1922

(2020) Possible Targets and Therapies of SARS-C V-2 Infection. Mini-Reviews in Medicinal Chemistry. pp. 1900-1907. ISSN 1389-5575

(2020) Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2. Pharmacological Research. p. 2. ISSN 1043-6618

(2020) Should we try the antiinflammatory natural product, celastrol, for COVID-19? Phytotherapy Research. pp. 1189-1190. ISSN 0951-418X

(2020) Various interferon (IFN)-inducible transmembrane (IFITM) proteins for COVID-19, is there a role for the combination of mycophenolic acid and interferon? Biochimie. pp. 50-52. ISSN 0300-9084